NCT03027557View on ClinicalTrials.gov

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

September 12, 2019

Conditions
Primary HyperparathyroidismParathyroid AdenomaParathyroid Hyperplasia
Interventions
DRUG

Cinacalcet 30 mg Tablet

Participants in one arm will receive 30 mg cinacalcet each day.

DRUG

Denosumab Inj 60 mg/ml

Participants in two arms will receive 60 mg Denosumab biannually.

OTHER

Placebo tablets

Participants in two arms will receive one placebo-tablet each day.

OTHER

Saline Injection (Placebo)

Participants in one arm will receive saline injections as placebo for denosumab.

Trial Locations (1)

9000

Aalborg University Hospital, Aalborg

All Listed Sponsors
collaborator

Aalborg University

OTHER

lead

Peter Vestergaard

OTHER

NCT03027557 - Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. | Biotech Hunter | Biotech Hunter